

# Diabetic Retinopathy Treatment World Market Segmentation and Major Players Analysis 2022

*Global Diabetic Retinopathy Treatment Market 2015 Analysis and Forecast to 2022*

PUNE, INDIA, September 2, 2016

/EINPresswire.com/ -- According to research, the Global [Diabetic Retinopathy Treatment](#) market is expected to reach \$10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors driving the market growth. However, Lack of accurate diagnosis, a lack of skilled ophthalmologist coupled with poor infrastructure and extended approval time for drugs are hampering the growth of global diabetic retinopathy market. Increase in awareness of diabetic retinopathy treatment and improvement of patient monitoring are some of the major trends in the market. The two main stages of diabetic retinopathy are non-proliferated and proliferated. Proliferated diabetic retinopathy is the mainly insecure stage and has the risk of detachment into the vitreous leading to severe vision loss.



Complete report details @

<https://www.wiseguyreports.com/reports/diabetic-retinopathy-treatment-global-market-outlook-2015>

North America leads the global diabetic retinopathy market due to vast number of aging population. The Asia Pacific diabetic retinopathy market is expected to witness profitable growth over the estimated period due to the occurrence of unmet needs in the developing countries such as China and India. These countries are expected to be the fastest growing diabetic retinopathy markets in Asia-Pacific region.

Some of the key players in the market include Regeneron Pharmaceuticals Inc., ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis PLC, BCN Peptides, Novartis AG, Ampio Pharmaceuticals, Kowa Group, Sirnaomics Incorporation, Abbott Laboratories Ltd, Glycadia Pharmaceuticals, Alcon Laboratories Inc. and Parexel International Corp.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/diabetic-retinopathy-treatment-global-market-outlook-2015>

Type of Treatments Covered:

- Intraocular Steroid Injection
- Vitrectomy
- Anti-Vascular Endothelial Growth Factor (VEGF) drug

- Laser Surgery

Disease Type Covered:

- Proliferative Diabetic Retinopathy (PDR)
- Non-Proliferative Diabetic Retinopathy (NPDR)

- o Moderate

- o Mild

- o Severe

End Users Covered:

- Ophthalmic Clinics
- Ambulatory Surgical Centers
- Hospitals
- Other End Users

Regions Covered:

- North America

- o US

- o Canada

- o Mexico

- Europe

- o Germany

- o France

- o Italy

- o UK

- o Spain

- o Rest of Europe

- Asia Pacific

- o Japan

- o China

- o India

- o Australia

- o New Zealand

- o Rest of Asia Pacific

- Rest of the World

- o Middle East

- o Brazil

- o Argentina

- o South Africa

- o Egypt

What our report offers:

- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/diabetic-retinopathy-treatment-global-market-outlook-2015>

## TABLE OF CONTENT

### 1 Executive Summary

### 2 Preface

#### 2.1 Abstract

#### 2.2 Stake Holders

#### 2.3 Research Scope

#### 2.4 Research Methodology

##### 2.4.1 Data Mining

##### 2.4.2 Data Analysis

##### 2.4.3 Data Validation

##### 2.4.4 Research Approach

#### 2.5 Research Sources

##### 2.5.1 Primary Research Sources

##### 2.5.2 Secondary Research Sources

##### 2.5.3 Assumptions

### 3 Market Trend Analysis

#### 3.1 Introduction

#### 3.2 Drivers

#### 3.3 Restraints

#### 3.4 Opportunities

#### 3.5 Threats

#### 3.6 End User Analysis

#### 3.7 Emerging Markets

### 4 Porters Five Force Analysis

#### 4.1 Bargaining power of suppliers

#### 4.2 Bargaining power of buyers

#### 4.3 Threat of substitutes

#### 4.4 Threat of new entrants

#### 4.5 Competitive rivalry

### 5 Global Diabetic Retinopathy Treatment Market, By Treatment type

#### 5.1 Introduction

#### 5.2 Intraocular Steroid Injection

#### 5.3 Vitrectomy

#### 5.4 Anti-Vascular Endothelial Growth Factor (VEGF) drug

#### 5.5 Laser Surgery

### 6 Global Diabetic Retinopathy Treatment Market, By Disease Type

#### 6.1 Introduction

#### 6.2 Proliferative Diabetic Retinopathy (PDR)

#### 6.3 Non-Proliferative Diabetic Retinopathy (NPDR)

##### 6.3.1 Moderate

##### 6.3.2 Mild

##### 6.3.3 Severe

### 7 Global Diabetic Retinopathy Treatment Market, By End User

#### 7.1 Introduction

#### 7.2 Ophthalmic Clinics

7.3 Ambulatory Surgical Centers

7.4 Hospitals

7.5 Other End Users

8 Global Diabetic Retinopathy Treatment Market, By Geography

8.1 North America

8.1.1 US

8.1.2 Canada

8.1.3 Mexico

8.2 Europe

8.2.1 Germany

8.2.2 France

8.2.3 Italy

8.2.4 UK

8.2.5 Spain

8.2.6 Rest of Europe

8.3 Asia Pacific

8.3.1 Japan

8.3.2 China

8.3.3 India

8.3.4 Australia

8.3.5 New Zealand

8.3.6 Rest of Asia Pacific

8.4 Rest of the World

8.4.1 Middle East

8.4.2 Brazil

8.4.3 Argentina

8.4.4 South Africa

8.4.5 Egypt

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures

9.2 Acquisitions & Mergers

9.3 New Product Launch

9.4 Expansions

9.5 Other Key Strategies

10 Company Profiling

10.1 Regeneron Pharmaceuticals Inc.

10.2 ThromboGenics

10.3 Genentech

10.4 Bayer Healthcare

10.5 Alimera Sciences

10.6 Actavis PLC

10.7 BCN Peptides

10.8 Novartis AG

10.9 Ampio Pharmaceuticals

10.10 Kowa Group

10.11 Sirnaomics Incorporation

10.12 Abbott Laboratories Ltd

10.13 Glycadia Pharmaceuticals

10.14 Alcon Laboratories Inc.

10.15 Parexel International Corp.

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=456543](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=456543)

Norah Trent  
wiseguyreports  
+1 646 845 9349 / +44 208 133 9349  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.